Kazuki Haruguhi

Kazuki Haruguhi

Auto-generated profile, based on publicly available information

Kazuki Haruguhi

Department of Vascular Surgery, IMS Fujimi General Hospital, Saitama Prefecture, Japan

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2026 in The Journal of Vascular Access
Verified
Journal Article
Closed access
HHHiroaki Haruguchi
Hiroaki Haruguchi
KHKazuki Haruguhi
Kazuki Haruguhi
Background: Arteriovenous fistulas (AVFs) are essential for long-term hemodialysis access, but recurrent stenosis remains a major clinical challenge. Drug-coated balloon (DCB) angioplasty demonstrates improved patency outcomes. However, factors influencing its durability are not fully understood. Purpose: This study aimed to evaluate clinical outcomes of DCB angioplasty for dysfunctional AVFs and to identify independent clinical and procedural predictors. Methods: In this retrospective, single-center cohort study, 195 hemodialysis patients underwent their first DCB angioplasty for significant AVF stenosis between April 2021 and February 2024. Patient demographics, lesion characteristics, and procedural details were analyzed. TLPP (freedom from clinically driven target lesion revascularization or access circuit thrombosis) was assessed using Kaplan–Meier analysis, and predictors of patency loss were evaluated with Cox proportional hazards modeling. Variables with strong collinearity were excluded from the multivariable Cox model; notably, post-DCB vessel diameter was omitted from the multivariable model due to correlation with balloon size. Results: TLPP at 6, 12, and 24 months was 68.5%, 33.7%, and 14.9%, respectively. In multivariable analysis, non-juxta-anastomotic lesions (HR 2.98, p < 0.001), antiplatelet therapy (HR 1.37, p = 0.048) were independently associated with an increased risk of TLPP loss. Conversely, a longer interval from prior PTA (HR 0.64, p < 0.001), and larger balloon size (HR 0.63, p = 0.003), were associated with reduced risk. Kaplan–Meier curves demonstrated superior outcomes for juxta-anastomotic lesions, patients without antiplatelet therapy, and those with longer prior PTA intervals, larger balloons, and larger post-DCB diameters. Conclusions: Juxta-anastomotic location, absence of antiplatelet therapy, longer prior PTA intervals, and larger DCB size are associated with improved TLPP. Kaplan–Meier analysis also indicated that larger post-DCB diameter was associated with improved TLPP.

11 January 2026 in The Journal of Vascular Access
Verified
Journal Article
Closed access
HHHiroaki Haruguchi
Hiroaki Haruguchi
KHKazuki Haruguhi
Kazuki Haruguhi
Background: Drug-coated balloons (DCBs) have shown promise in prolonging arteriovenous fistula (AVF) patency by inhibiting neointimal hyperplasia. However, few studies have longitudinally evaluated vascular remodeling after DCB treatment using ultrasound. This study aimed to evaluate vascular remodeling after DCB treatment using high-frequency ultrasound. Methods: In this retrospective single-center study, 50 patients with single AVF stenosis were treated with DCB and followed by ultrasound at four time points: pre-treatment, immediately post-treatment, 3 months, and 6 months. Patients were classified into short-term ( n = 24; reintervention within 6–9 months) and long-term ( n = 26; patency ⩾18 months) groups. The mean follow-up time in the long-term group was 24.5 months. Nineteen patients had complete ultrasound data every 3 months up to 15 months. Parameters included lumen cross-sectional area (L-CSA), external cross-sectional area (E-CSA), and intima-media thickness area (IMT area). Results: Baseline demographics were similar between groups. L-CSA was significantly larger in the long-term group both immediately post-DCB (14.4 ± 5.9 vs 9.9 ± 3.9 mm², p < 0.001) and at 6 months (5.3 ± 2.2 vs 3.1 ± 1.3 mm², p < 0.001). E-CSA was also greater in the long-term group at 6 months (21.7 ± 8.8 vs 14.7 ± 5.0 mm², p < 0.001). While there was no significant difference in IMT area immediately post-treatment, it was significantly greater in the long-term group at 6 months (16.3 ± 7.8 vs 11.6 ± 7.8 mm², p < 0.001). No significant changes in L-CSA, E-CSA, or IMT were observed beyond 6 months. Conclusions: Regular ultrasound examinations enable accurate evaluation of vascular remodeling. Initial vessel dilation and sustained external diameter enlargement may contribute to long-term morphological stability and patency following DCB treatment.

6 July 2026 in The Journal of Vascular Access
Verified
Journal Article
Closed access
HHHiroaki Haruguchi
Hiroaki Haruguchi
KHKazuki Haruguchi
Kazuki Haruguchi
TITomoaki Itoh
Tomoaki Itoh
NYNorifumi Yoshimoto
Norifumi Yoshimoto
Background: Juxta-anastomotic stenosis is a major cause of arteriovenous fistula (AVF) dysfunction. Although drug-coated balloons (DCB) have demonstrated clinical benefit, the associated morphological changes compared with plain old balloon angioplasty (POBA) remain poorly defined. This study aimed to characterize vascular remodeling patterns after DCB and POBA using ultrasonographic cross-sectional area (CSA) analysis. Methods: In 41 patients with juxta-anastomotic AVF stenosis, all initially underwent POBA and subsequently DCB for recurrent stenosis. Luminal cross-sectional area (L‑CSA), external vessel cross-sectional area (E‑CSA), and vessel wall area (VWA) were assessed pre-treatment, post-treatment, and at 3 months. Longitudinal mixed-effects and baseline-adjusted models evaluated remodeling patterns and independent treatment effects. Exploratory intima–media thickness (IMT) analysis was performed. Results: Median target lesion primary patency (TLPP) was longer after DCB than POBA (10.8 vs 3.3 months). At 3 months, L‑CSA and E‑CSA were significantly larger after DCB, whereas VWA did not differ between treatments. Longitudinal mixed-effects models showed significant treatment-by-time interactions for L‑CSA and E‑CSA, with progressive luminal narrowing and external vessel shrinkage after POBA that were attenuated after DCB, while VWA increased similarly in both groups. Baseline-adjusted models confirmed that DCB was independently associated with larger 3-month L‑CSA and E‑CSA suggesting that the patency benefit observed after DCB was associated with preservation of external vessel dimensions rather than suppression of wall thickening. Exploratory analyses further showed that, despite similar changes in IMT area, IMT thickness increased more slowly after DCB, suggesting a possible contribution to sustained E‑CSA preservation. Conclusion: DCB provided improved clinical outcomes in juxta-anastomotic stenosis. These findings suggest that improved outcomes after DCB may be associated with preservation of external vessel architecture and mitigation of constrictive remodeling, potentially supported by IMT suppression, rather than a predominant inhibitory effect on wall thickening. This suggests a site-specific mechanism of DCB action in the hemodynamically stressed juxta-anastomotic segment.